1. Home
  2. VFF vs DMAC Comparison

VFF vs DMAC Comparison

Compare VFF & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Village Farms International Inc.

VFF

Village Farms International Inc.

HOLD

Current Price

$3.23

Market Cap

396.2M

Sector

N/A

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$7.98

Market Cap

428.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VFF
DMAC
Founded
1989
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.2M
428.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VFF
DMAC
Price
$3.23
$7.98
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
N/A
$15.50
AVG Volume (30 Days)
1.1M
232.5K
Earning Date
03-12-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.19
N/A
Revenue
$351,979,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.43
N/A
P/E Ratio
$17.05
N/A
Revenue Growth
56.61
N/A
52 Week Low
$0.45
$3.19
52 Week High
$4.99
$10.42

Technical Indicators

Market Signals
Indicator
VFF
DMAC
Relative Strength Index (RSI) 42.81 48.54
Support Level $2.98 $7.47
Resistance Level $3.39 $8.24
Average True Range (ATR) 0.16 0.57
MACD -0.02 -0.04
Stochastic Oscillator 43.33 42.14

Price Performance

Historical Comparison
VFF
DMAC

About VFF Village Farms International Inc.

Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Leli . The company makes majority of its revenue from the Produce segment.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: